Ruta Nonacs

About Ruta Nonacs, MD PhD

This author has not yet filled in any details.
So far Ruta Nonacs, MD PhD has created 320 blog entries.

Maternal Self-Efficacy as a Risk Factor for Postpartum Depression and Anxiety

Postpartum depression first gained medical attention in the 1970’s.  While postpartum depression is similar to depression occurring at other times in a woman’s life, we have learned over time that many women with what we [...]

By |2025-12-11T09:48:30-04:00April 13th, 2021|Anxiety Disorders, Depressive Disorders, Postpartum Psychiatric Disorders|Comments Off on Maternal Self-Efficacy as a Risk Factor for Postpartum Depression and Anxiety

Essential Reads: Using Neuroimaging to Visualize the Impact of Maternal Depression on the Developing Brain

When a woman comes in for a consultation regarding the use of medications during pregnancy, we spend most of our time reviewing the potential risks of exposure to medications during pregnancy.  However, we must also [...]

By |2024-03-25T08:29:04-04:00February 24th, 2021|Child Outcomes, Depressive Disorders, Essential Reads, Psychiatric Disorders During Pregnancy|Comments Off on Essential Reads: Using Neuroimaging to Visualize the Impact of Maternal Depression on the Developing Brain

Prenatal Exposure to Valproic Acid Linked to Increased Risk for Autism, ADHD

Prenatal exposure to valproate has been associated with an elevated risk (10%) for a broad range of congenital malformations including neural tube defects, as well as adverse neurodevelopmental sequelae, including lower IQ and developmental delays [...]

By |2025-06-26T09:07:37-04:00February 9th, 2021|Anti-Epileptic Drugs, Neurodevelopmental Disorders, Outcomes, Pregnancy & Medications|Comments Off on Prenatal Exposure to Valproic Acid Linked to Increased Risk for Autism, ADHD

Taking a Closer Look at Motor Development in Children with Prenatal Exposure to Antidepressants

While we have data to support the use of antidepressants, including the selective serotonin reuptake inhibitors (SSRIs) and the serotonin norepinephrine reuptake inhibitors (SNRIs), during pregnancy, most studies have focused on risk of congenital [...]

By |2024-03-25T08:31:46-04:00January 19th, 2021|Antidepressants, Child Outcomes, Outcomes, Pregnancy & Medications|Comments Off on Taking a Closer Look at Motor Development in Children with Prenatal Exposure to Antidepressants

Postpartum Depression: Unipolar or Bipolar?

About 15% of women will experience postpartum depression after the birth of a child.  While most of those women will have unipolar depression, a certain number of women will have bipolar depression.  At this juncture, [...]

By |2024-04-14T16:06:43-04:00January 12th, 2021|Bipolar Disorder, Depressive Disorders, Diagnosis & Screening, Postpartum Depression, Postpartum Psychiatric Disorders, Prevalence & Risk Factors|Comments Off on Postpartum Depression: Unipolar or Bipolar?

Essential Reads: Screening for Perinatal Anxiety Disorders

Anxiety symptoms are common during pregnancy and the postpartum period.  According to a recent meta-analysis from Fawcett and colleagues, about one out of every five women has at least one type of anxiety disorder [...]

By |2024-04-14T16:16:16-04:00December 9th, 2020|Anxiety Disorders, Diagnosis & Screening, Essential Reads, Postpartum Psychiatric Disorders, Psychiatric Disorders During Pregnancy|Comments Off on Essential Reads: Screening for Perinatal Anxiety Disorders

Prenatal Valproic Acid (Depakote) Exposure Increases Risk for Neurodevelopmental Disorders

While we have considerable information regarding the teratogenic risk associated with prenatal exposure to various antiepileptic drugs (AEDs), we have considerably less information on the impact of exposure to AEDs on behavioral outcomes in [...]

By |2025-06-26T09:07:38-04:00November 11th, 2020|Anti-Epileptic Drugs, Neurodevelopmental Disorders, Outcomes, Pregnancy & Medications|Comments Off on Prenatal Valproic Acid (Depakote) Exposure Increases Risk for Neurodevelopmental Disorders

More Data on the Neuroactive Steroid Zuranolone for Postpartum Depression

While we have heard a lot about brexanolone, marketed by Sage Therapeutics as Zulresso, for the treatment of postpartum depression, an oral version of this novel antidepressant – SAGE 217 or zuranolone – has been [...]

By |2026-03-10T12:50:13-04:00September 14th, 2020|Medication, Postpartum Depression, Postpartum Psychiatric Disorders, Treatment|Comments Off on More Data on the Neuroactive Steroid Zuranolone for Postpartum Depression
Go to Top